2 ▶ Classic single-asset biotech risk played out. Tenax’s Phase 3 failed its primary endpoint in PH-HFpEF. Shares cratered ~90%. Wall Street rewrote the story in one trading day. aktiego.com/sectors/biot... $TENX 0 comments · 1d ago · by AktieGo #$tenx#biotech
3 ▶ From $13.45 to under $2. Tenax’s Phase 3 miss was decisive. Primary endpoint failed (p=0.63). A sicker-patient subgroup looked better, but the overall trial did not. aktiego.com/sectors/biot... $TENX 0 comments · 1d ago · by AktieGo #$tenx#pharma
▶